• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Protara Therapeutics Inc.

    8/6/24 4:16:01 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TARA alert in real time by email
    S-8 1 ea0210480-s8_protara.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on August 6, 2024

    Registration No. 333-            

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    Protara Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   20-4580525
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    345 Park Avenue South, Third Floor

    New York, NY 10010

    (Address of Principal Executive Offices) (Zip Code)

     

    2024 Equity Incentive Plan

    2024 Employee Stock Purchase Plan

    (Full title of the plans)

     

    Jesse Shefferman

    President and Chief Executive Officer

    Protara Therapeutics, Inc.

    345 Park Avenue South, Third Floor

    New York, NY 10010

    (Name and address of agent for service)

     

    (646) 844-0337

    (Telephone number, including area code, of agent for service)

     

    Copies to:

     

    Mary J. Grendell, Esq.
    General Counsel and Corporate Secretary
     

    Robert W. Downes

    Sullivan & Cromwell LLP

    Protara Therapeutics, Inc.   125 Broad St.
    345 Park Avenue South, Third Floor   New York, NY 10004
    New York, NY 10010   (212) 558-4000
    (646) 844-0337    

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐ 

     

     

     

     

     

     

    PART I

     

    Information Required in the Section 10(a) Prospectus

     

    The information called for by Part I of Form S-8 is omitted from this Registration Statement in accordance with Rule 428 of the Securities Act of 1933, as amended (the “Securities Act”), and the instructions to Form S-8. In accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”) and the instructions to Form S-8, such documents are not being filed with the Commission.

     

    The documents containing the information specified in Part I will be delivered to the participants of the 2024 Equity Incentive Plan and the 2024 Employee Stock Purchase Plan, as specified by Rule 428(b)(1) of the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    1

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    ITEM 3. Incorporation of Documents by Reference.

     

    The registrant hereby incorporates by reference into this Registration Statement the following documents previously filed by the registrant with the Commission (other than portions of Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits related to such items or other portions of documents filed with the Commission which were furnished, but not filed, pursuant to applicable rules promulgated by the Commission): 

     

      ● the Company’s Annual Report on Form 10-K filed with the Commission on March 13, 2024; and

     

      ● the Company’s Quarterly Reports on Form 10-Q filed with the Commission May 2, 2024 and August 6, 2024; for the fiscal quarters ended March 31, 2024 and June 30, 2024, respectively; and

     

      ● the Company’s Current Reports on Form 8-K filed with the Commission on March 18, 2024, April 5, 2024 and June 10, 2024; and

     

      ● the description of the Company’s Common Stock contained in Exhibit 4.2 to the Company’s Annual Report on Form 10-K filed with the Commission on March 11, 2021, including any amendments or reports filed for the purpose of updating such description.

     

    In addition, all reports and other documents subsequently filed by the registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

     

    II-1

     

     

    ITEM 8. EXHIBITS.

     

    Exhibit
    Number
      Description
         
    4.1   Sixth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on October 27, 2014).
         
    4.2   Certificate of Amendment to the Sixth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on January 10, 2020).
         
    4.3   Second Certificate of Amendment to the Sixth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to the Registrant’s Quarterly Report on Form 10-Q, filed with the Commission on May 13, 2020).
         
    4.4   Second Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed with the Commission on August 3, 2017).
         
    4.5   Certificate of Designation of Preferences, Rights and Limitations of Series 1 Convertible Preferred Stock (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed with the Commission on January 10, 2020).
         
    4.6   Certificate of Amendment to the Certificate of Designation of Preferences, Rights and Limitations of Series 1 Convertible Non-Voting Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on September 23, 2020).
         
    4.7   Registration Rights Agreement, dated as of September 23, 2019, by and among the Registrant and the institutional investors named therein (incorporated by reference to Exhibit 10.5 to the Registrant’s Current Report on Form 8-K, filed with the Commission on September 24, 2019).
         
    4.8   Registration Rights Agreement, dated April 5, 2024 (incorporated by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K, filed with the SEC on April 5, 2024).
         
    4.9   Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on January 10, 2020).
         
    5.1*   Opinion of Sullivan & Cromwell LLP.
         
    23.1*   Consent of Ernst & Young LLP.
         
    23.2*   Consent of Sullivan & Cromwell LLP (included in Exhibit 5.1).
         
    24.1*   Power of Attorney (included on signature page).
         
    99.1    2024 Equity Incentive Plan (incorporated by reference to Exhibit 99.1 to the Registrant’s Quarterly Report on Form 10-Q, filed with the Commission on August 6, 2024).
         
    99.2   2024 Employee Stock Purchase Plan (incorporated by reference to Exhibit 99.2 to the Registrant’s Quarterly Report on Form 10-Q, filed with the Commission on August 6, 2024).
         
    107*   Filing Fee Table.

     

    * Filed herewith.

     

    II-2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York on August 6, 2024.

     

      PROTARA THERAPEUTICS, INC.
         
      By: /s/ Jesse Shefferman
        Jesse Shefferman
        President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jesse Shefferman, Patrick Fabbio and Mary J. Grendell, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature   Title   Date
             
    /s/ Jesse Shefferman   President and Chief Executive Officer and Director   August 6, 2024
    Jesse Shefferman   (Principal Executive Officer)    
             
    /s/ Patrick Fabbio   Chief Financial Officer   August 6, 2024
    Patrick Fabbio   (Principal Financial Officer)    
             
    /s/ Hannah Fry   Vice President, Controller   August 6, 2024
    Hannah Fry   (Principal Accounting Officer)    
             
    /s/ Luke Beshar   Chairman of the Board of Directors   August 6, 2024
    Luke Beshar        
             
    /s/ Barry Flannelly   Director   August 6, 2024
    Barry Flannelly, Pharm.D.        
             
    /s/ Roger Garceau   Director   August 6, 2024
    Roger Garceau, M.D.        
             
    /s/ Jane Huang   Director   August 6, 2024
    Jane Huang, M.D.        
             
    /s/ Richard Levy   Director   August 6, 2024
    Richard Levy, M.D.        
             
    /s/ Gregory P. Sargen   Director   August 6, 2024
    Gregory P. Sargen        
             
    /s/ Cynthia Smith   Director   August 6, 2024
    Cynthia Smith        
             
    /s/ Michael Solomon   Director   August 6, 2024
    Michael Solomon, Ph.D.        

     

     

    II-3

     

     

    Get the next $TARA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TARA

    DatePrice TargetRatingAnalyst
    1/7/2026$24.00Overweight
    Piper Sandler
    4/16/2025$12.00Sector Outperform
    Scotiabank
    3/14/2025Overweight
    Cantor Fitzgerald
    7/10/2023$22.00Buy
    Guggenheim
    11/8/2021$32.00 → $34.00Outperform
    Oppenheimer
    More analyst ratings

    $TARA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Protara Therapeutics with a new price target

    Piper Sandler initiated coverage of Protara Therapeutics with a rating of Overweight and set a new price target of $24.00

    1/7/26 9:14:32 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scotiabank initiated coverage on Protara Therapeutics with a new price target

    Scotiabank initiated coverage of Protara Therapeutics with a rating of Sector Outperform and set a new price target of $12.00

    4/16/25 8:13:38 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald initiated coverage on Protara Therapeutics

    Cantor Fitzgerald initiated coverage of Protara Therapeutics with a rating of Overweight

    3/14/25 7:42:48 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARA
    SEC Filings

    View All

    SEC Form 424B7 filed by Protara Therapeutics Inc.

    424B7 - Protara Therapeutics, Inc. (0001359931) (Filer)

    2/2/26 4:30:21 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Protara Therapeutics, Inc. (0001359931) (Filer)

    12/15/25 4:15:24 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B7 filed by Protara Therapeutics Inc.

    424B7 - Protara Therapeutics, Inc. (0001359931) (Filer)

    12/9/25 4:16:14 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Levy Richard S bought $63,800 worth of shares (20,000 units at $3.19), increasing direct ownership by 65% to 51,000 units (SEC Form 4)

    4/A - Protara Therapeutics, Inc. (0001359931) (Issuer)

    5/19/25 4:10:10 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Levy Richard S bought $63,800 worth of shares (20,000 units at $3.19), increasing direct ownership by 65% to 51,000 units (SEC Form 4)

    4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

    5/16/25 4:05:07 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA) ("Protara" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to one newly-hired employee. The Compensation Committee of Protara's Board of Directors approved an aggregate of 10,200 stock option awards and 5,100 RSU awards to one new employee from the Inducement Plan, as inducements material to the new employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4). Such option awards were granted on February 2, 20

    2/2/26 4:05:25 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium

    NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that updated interim data from the cohort of BCG-Unresponsive non-muscle invasive bladder cancer (NMIBC) patients in the ongoing Phase 2 ADVANCED-2 trial of TARA-002 will be featured at the upcoming American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place from February 26, 2026 to February 28, 2026 in San Francisco. The poster presentation will include updated safety and efficacy data from approximately 25 six-month evaluable BCG-Unresponsive N

    1/22/26 8:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones

    On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 2026 Received Breakthrough Therapy and Fast Track designations for TARA-002 in LMs; regulatory update expected in 1H 2026 Dosed first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on long-term parenteral support and expect to report interim results in 2H 2026 Recently completed approximately $86 million public offering extending cash runway into 2028 NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of canc

    1/12/26 7:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Fabbio Patrick covered exercise/tax liability with 3,261 shares, decreasing direct ownership by 5% to 64,115 units (SEC Form 4)

    4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

    1/27/26 4:10:13 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    VP, Controller Fry Hannah covered exercise/tax liability with 1,457 shares, decreasing direct ownership by 3% to 42,723 units (SEC Form 4)

    4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

    1/27/26 4:10:15 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO and President Shefferman Jesse covered exercise/tax liability with 8,732 shares, decreasing direct ownership by 0.85% to 1,021,832 units (SEC Form 4)

    4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

    1/27/26 4:10:07 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARA
    Financials

    Live finance-specific insights

    View All

    Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients

    TARA-002 demonstrates 72% complete response rate at any time in BCG-Naïve patientsTARA-002 demonstrates a 69% complete response rate at the 6-month landmark and a 50% complete response rate at the 12-month landmark in BCG-Naïve patientsFavorable safety and tolerability profile observed with no Grade 3 or greater treatment-related adverse events reportedCompany obtained written feedback from FDA on registrational path forward for TARA-002 in BCG-Naïve patientsCompany remains on track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in the registrational cohort of the ADVANCED-2 trial in Q1 2026 Company expects to complete enrollment of the BCG-Unre

    12/3/25 8:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025

    NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will host a conference call and live webcast at 8:30 am ET on Wednesday, December 3, 2025, to review new data from an interim analysis of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in BCG-Naïve patients with non-muscle invasive bladder cancer (NMIBC). The data will be featured during a poster session at the 26th Annual Meeting of the Society of Urologic Oncology (SUO). The Company will also provide an update on feedback from the U.S. Food and Drug Administrat

    12/1/25 4:15:00 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

    80% of patients that completed treatment and 100% of patients that completed the eight-week response assessment achieved clinical successClinical success achieved with one or two doses of TARA-002 in 88% of patients TARA-002 demonstrated favorable safety and tolerability profile with no serious adverse events reportedCompany to host conference call and webcast featuring Key Opinion Leader Dr. Jesse Jones at 8:30 a.m. ET NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced positive interim results from its ongoing Phase 2 open-label S

    11/19/25 8:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Protara Therapeutics Inc.

    SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)

    12/17/24 4:02:03 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Protara Therapeutics Inc.

    SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)

    11/18/24 6:01:42 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Protara Therapeutics Inc.

    SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)

    11/14/24 1:00:40 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARA
    Leadership Updates

    Live Leadership Updates

    View All

    Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

    Presentation of interim analysis from approximately 25 six-month evaluable BCG-Unresponsive patients in the ongoing ADVANCED-2 trial expected at a medical conference in 1Q 2026 Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support on track for 3Q 2025   On track to provide an interim update from the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients in 4Q 2025 Cash, cash equivalents and investments of approximately $146 million as of June 30, 2025, expected to support planned operations into mid-2027 NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage com

    8/11/25 8:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics Announces Addition to the Russell 3000® Index

    NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the Company has been added as a member of the broad-market Russell 3000® Index as part of the annual reconstitution, effective at the open of U.S. equity markets today, June 30, 2025. "Protara's inclusion in the Russell 3000® Index is a reflection of the progress that we have made executing across our pipeline, including the advancement of clinical trials for TARA-002 in non-muscle invasive bladder cancer and lymphatic malformations and the development of our IV Choline Chlorid

    6/30/25 8:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer

    NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of William "Bill" Conkling as Chief Commercial Officer. He brings more than two decades of experience developing and commercializing novel cancer and rare disease therapeutics to Protara. "It is a pleasure to welcome Bill, a deeply experienced and proven commercial leader," said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. "With an impressive track record building commercial organizations and successfully launching oncology and rare disease prod

    6/2/25 4:04:01 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care